Absci Corp (ABSI)
3.98
-0.39
(-8.92%)
USD |
NASDAQ |
Jun 14, 16:00
4.00
+0.02
(+0.50%)
After-Hours: 20:00
Absci Cash from Financing (Quarterly): 81.18M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 81.18M |
| December 31, 2023 | -1.235M |
| September 30, 2023 | -0.924M |
| June 30, 2023 | -1.22M |
| March 31, 2023 | -1.104M |
| December 31, 2022 | 1.393M |
| September 30, 2022 | -0.921M |
| June 30, 2022 | 5.823M |
| March 31, 2022 | -1.058M |
| Date | Value |
|---|---|
| December 31, 2021 | -1.296M |
| September 30, 2021 | 208.39M |
| June 30, 2021 | -0.474M |
| March 31, 2021 | 129.58M |
| December 31, 2020 | 64.39M |
| September 30, 2020 | -0.311M |
| June 30, 2020 | 6.326M |
| March 31, 2020 | 0.566M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.296M
Minimum
Dec 2021
208.39M
Maximum
Sep 2021
28.77M
Average
-0.311M
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | -311.30M |
| CytomX Therapeutics Inc | 0.174M |
| Bristol-Myers Squibb Co | 14.64B |
| Recursion Pharmaceuticals Inc | 13.90M |
| NovaBay Pharmaceuticals Inc | -0.597M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.86M |
| Cash from Investing (Quarterly) | -76.68M |
| Free Cash Flow | -62.38M |
| Free Cash Flow Per Share (Quarterly) | -0.1797 |
| Free Cash Flow to Equity (Quarterly) | -16.99M |
| Free Cash Flow to Firm (Quarterly) | -17.69M |
| Free Cash Flow Yield | -16.67% |